Table 3.

IC₅₀ and TGI values in μM of compound 1r and KIST101029 over ovarian, prostate, and breast cancer cell lines.

	Cell line	5-dose results of Compound 1r		5-dose results of KIST101029
		IC50a	TGIb	IC50a	TGIb
Ovarian cancer	IGROV1	0.70	43.3	0.06	56.9
	OVCAR-3	0.24	1.47	0.02	0.05
	OVCAR-4	1.08	26.0	0.24	50.0
	OVCAR-5	1.38	>50	0.20	>100
	OVCAR-8	1.26	9.96	0.06	>100
	NCI/ADR-RES	0.34	>50	0.04	26.4
Prostate cancer	PC-3	0.38	10.40	0.06	>100
	DU-145	1.30	4.67	0.04	0.10
Breast cancer	MCF7	0.15	6.86	0.04	54.0
	MDA-MB-231/ATCC	0.84	2.32	0.16	3.42
	HS 578T	0.34	2.43	0.99	97.2
	T-47D	1.78	27.5	0.08	7.46
	MDA-MB-468	0.30	3.14	0.03	0.10
HS-27 Fibroblasts		5.72	-	0.30	-

^aIC₅₀ is the concentration producing 50% inhibition. The results are expressed as means of duplicate experiments.

^bTGI is the concentration producing 100% inhibition.